Loading Events

Webinar #10 – How & why to use human cellular models to study SYNGAP1

  • This event has passed.

November 5, 2020 @ 12:00 pm – 1:00 pm EST

Here are our introductory comments: 

Dr. Marcelo Coba gave a talk on November 5th at noon Pacific, titled How & why to use human cellular models to study Syngap1.  Dr. Coba has SRF grant 20-1 to support organoid work as described in this USC article.

Webinar Overview

Dr. Marcelo Coba is a psychiatric researcher at the USC school of medicine. He starts this webinar by explaining the synapse and postsynaptic density (PSD), a protein-dense region after the synapse where SYNGAP1 is one of the most abundant proteins. Dr. Coba then goes over how his lab uses mass spectrometry to identify the molecules SYNGAP1 binds to. This leads to an in-depth discussion about protein-protein interaction networks which regulate specific functions. Dr. Coba explains how SYNGAP1 is a hub, a protein which has many connections, in the protein network that regulates synaptic function, so a mutation in SYNGAP1 is likely to disrupt that entire protein-protein interaction network. He uses human models to do his research on SYNGAP1, and while they have the human gene and a genetic background which are good for research, they are immature models, “fetal-like,” and poorly characterized which make them difficult. He closes the webinar by saying he is working on building the proper model because while human models are important, his current model is not easy to work with.

Other Relevant Publications by Dr. Coba

THIS IS FOR TRANSCRIPT ONLY:

0:04okay so it’s 12. marta do you want to do introductions

0:09yes sure i’m ready go for it okay then um we are very excited to

0:17continue the srf webinar series the goals of the series are one getting

0:22you closer to the science to making you aware of the results that is being done

0:27and the opportunities to participate and treat empower your communications with

0:33clinicians uh we also want to remind you that our next webinar in the series is

0:38with dr stefan sanders on sigmund god one in the developing human

0:44cortex tomorrow friday november 6 at 9 00 a.m pacific uh the talk today is how and why to use

0:52human cells models to study singaporean by dr marcelo pablo cova dr

1:00kova is an associate professor of psychiatry and behavioral science at the university of southern

1:06california keck school of medicine dr kova’s impressive educational background

1:12includes a doctoral of pharmacy and post-doctoral work in neuroscience his education sets him

1:19apart and aligns well with sync up patient’s needs dr kova has a long long-standing

1:25interest in the role of proteins like singaporean that are important in the synaptic

1:30function synaptic plasticity learning and memory he wants to help us

1:36to understand the molecular and cellular changes that occur in hours in gapions professor

1:43co-op proposed a plan to address these essential and complicated questions the proposed work includes

1:50groundbreaking new ways to describe the effects of non-pathogenic synchron

1:55variants in the neurology neuronal cells and critical to find

2:00molecular targets for potential medications dr kova has a close working relationship

2:07with srf and has been generous sharing his ideas and listening to parents

2:12for several years dr kova has been working on cinca 1 encephalopathy now

2:19he’s asking the syngap research formed to support his work he is optimistic this will eventually

2:26lead to better outcomes in translational research we as a group

2:31feel privileged and lucky to have dr koa working with us and we are thrilled to support his work

2:39after this briefing sort of introduction i wanted to let you know a recorded version of the this webinar

2:45will be available on the srf website by the end of the presentation you will have opportunity to get your

2:52questions answered we love to hear from you please write your questions in the chat

2:58for those of you just join us welcome and our talk today is how and why to use

3:04human cells cellular models to study think of one by dr marcelo pablo okay

3:12marcelo thank you martin thank you all the guys as a ref for the invitation and yeah

3:20i will show would be some briefly um just some

3:28brief things about how to use it or what are we going to do what we are doing with human models and

3:34things that at least to try to make clear what we can get what we are trying to do but hopefully it’s not in a very

3:42complicated uh way so we’re going to briefly this is theOutline

3:48outline what i’m going to discuss briefly i’m going to to say well how would be my path with sync up on my rediscovery of syngap in

3:55the last years and i were given my introduction of sigmoid i’m sure that you have an

4:01introduction of single one from every speaker and you know really a lot and i think that is

4:07going to be a bit different and then we’re going to describe a bit about the molecular composition of the

4:13synapses the kind of synesthetes that we have in these human models how we can use them

4:18approaches and a couple of examples some mutations that sync up and the kind of phenotype that we can see in these

4:25cellular models so let meBackground

4:32so when i started with singapore bumping into singapore i’m originally from argentina and i moved to england to cambridge uk

4:40at this place within the welcome trust sanger institute where that’s a play a big part in

4:45decoding the human genome in the early 2000s and i moved to work without america really with at the

4:52laboratory of seth grant which has an interested in synaptic

4:57signaling and he started to do it in different models of of synaptic dysfunction during mutations

5:04in different components of the synapse and in 2002 he published the first animal model of

5:10sync up it was a happy sufficient model so it was a a mutation in sync up that wiped out

5:17around 50 of the total protein levels which is many of the of patients

5:24i have that particular phenotype and as i said at that time there were very

5:30few people working on on singapore probably was rick hubeny later is gabbing coming from that group

5:37american eddie and seth who got the the first animal model and it wasn’t if you want a low-key

5:43publication in general neuroscience is not one of the top showmen so that’s just to have an idea

5:48what was the interest in the freelancing gap not many people working uh on that particular

5:54sheen protein and and also you don’t get the best publications on studying that more like you but my

6:01interest was in synaptic function really not no i didn’t move there just to work on singapore was just trying to

6:07address just general mechanisms of how the synapse work in particular the post-synaptic side so you have a

6:13pre-synaptic side and at the other side of the center you have the post-synaptic side so

6:18mostly working on on on that side of the synapse trying to address mechanisms of learning

6:24in memory what we define as synaptic plasticity very basic science uh

6:30questions and sync up was one of these uh molecules involved so we’ve been around with that

6:37when i moved there singapore’s one of these molecules the group was trying to knock down or just get mutation to as many components

6:44of the synapse as possible so singapore wasn’t really an another one we were used to

6:50compare results with other models we they were always around with with the single bonus model but i always

6:57remember one day and it was in 2009 that i bumped into that publication and

7:02really really struck me because at that point we were doing really what i consider basic uh

7:09neuroscience addressing mechanisms really intricate mechanism did you have one receptor being a

7:16more or less receptor of the membrane what is happening with the electrical activity of the synapse it

7:22this kind of thing with each particular mutant model but then it did we

7:27got this publication it was in 2009 it was the first uh report

7:35of patients with mutation in synagogue and i really i remember that day sitting at the office because and it was to me

7:42like we were working with an animal model and i can see that some of these patients that that reported in that paper had

7:48really a similar mutation that it was in the animal model that we were

7:53studying that is like happily sufficient model and that was to me the first uh

7:59at least realizing that what we were doing it has this uh connection to to real people not just

8:06who were doing basic mechanisms with in synapses and the main thing that

8:12happened you can see that first paper comes 2009 and then in 2000 in 2002 at least the the animal model the rick

8:19and me published on singap before that uh in 2009 which

8:25is it was seven years later that we just started getting data from patients and

8:30that was a one-off because it took some other many more years to start getting more and more patients

8:35and the main reason on that it was just the cognitive human genome just getting embedded and better not

8:41just a draft and then improvising sequencing analysis and because of that we are getting uh on this position today

8:48and and finding patients many many more patients and the sanger centerSanger Center

8:55was a place that you were doing on a larger scale a world that you will learn there it was high throughput it was high

9:01throughput everything you were sequencing genomes of everything any organism that you that you can get

9:09proteomes which is the counterpart of the genome is just addressing how many proteins a particular cell

9:16or compartment has we were deriving new technologies there was a particular

9:21project with it was called the mouse project which it means that just wipe out every possible sheen that they can do

9:28from the mouse so you will get more than 20 000 different lights of mice this is not very well known they

9:35have several thousands already done and they are for free really for investigators but it was that

9:40kind of thing so when i move it up from there i still have that idea of working on my lab at the silcaLab

9:47neurogenetic institute that late for usc it was this approach working on larger scale not focusing in

9:54one molecule so at that time still singapore was that one molecule

9:59that i have this interest but among many other molecules are the synapse so still we were publishing during these

10:06years on synga but with that thing in mind i think this one’s just one more component of the synapse

10:12and then it was i think it was 2017 or 2018 that i met hans that mike and the

10:18singapore research foundation and building up this a connection with them

10:23and getting all knowing the patients that kids with mutations in in sync gap and then to me

10:29what this is what i would call the rediscovering syngap and starting being back connected to

10:36to this molecule of the synonyms and still working with this system biology approach but probably with the focus on sync up now

10:42it’s in the lab so as i say it’s still the systemSyngap

10:48biology approach and we i still the sanger got me imprint on me

10:53this thing on not looking at one molecule at a time but trying to get it within the context of all the

11:00molecules that are surrounding uh your protein of interest in this case

11:06so it was a well how would this cripes in gap of how we seem sync up you have seen this picture many many times

11:12so syngap is what we described in modular protein you have different domains that you can

11:18see here with this funny name like ph which is a protein domain that you binds

11:23other proteins are lipids a c2 domain that binds calcium and this

11:28allows regulation of calcium single by calcium rascal which is an enzyme kind of

11:34function so it’s it’s a model it’s a domain that has performs a function in the cell

11:40a region of the product that not many people talks about which is a domain of an identified function but it’s a structure

11:46there that nobody knows what it does that’s the name the domain of unidentified

11:51functions so you don’t know what is it doing and at the c terminal let me

11:58see oops because i cannot see

12:14okay another c term they have a pdc ligand which is also a protein domain ligand that it

12:20allows sync up to bind to other proteins but what i’m showing that is that i like

12:26to see these the proteins as and of the pro or these regions of the protein that we call protein domains are

12:32modules of functional modules i like to define what a molecule can do

12:38by the composition of the protein domain so in this case you have what is the function of

12:43singapore is defined by all these collections of or protein domain that it has

12:49and why that this important because those domains they might have a particular function that they might not have

12:56a function per se more like just to associate to other things which is the case of the ph the pdc

13:03ligand and some other regions of on the molecule so i’m not going to describe much what

13:10is known about the rascal domain of the peristalsian domain you you may hear many talks on that

13:15most of the work that has been done on syngap it’s mostly associated with the

13:20pedestal ligand domain what is it doing this region of the protein it’s not much

13:26known what are the functional consequences of mutations in the rascal domain of or or

13:34why this is really needed at the synapseThe synapse

13:39so you might be probably you’ve seen from other talks these

13:45kind of pictures this is uh you have a different collection of cartoons a picture of what is the synapse

13:51so you have here a sentence which is composed by the presynaptic

13:57part which is released neurotransmitter on the postsynaptic site

14:02i know it’s not working

14:07and what did you have here the same thing but when an electron microscope picture of the presynaptic opposing optic side there’s

14:14a synaptic vesicle there and here is the postsynaptic side with this electrode insulation this dark

14:19region there is what we call the postsynaptic dentist city or psd you have a high amount of

14:26zinc up at this region which you as you probably know and it’s one of the

14:32most abundant proteins there so good thing with this well i would think why we know

14:38so much about the pst and the molecular composition of the psds because we can isolate by biochemical fractionation we

14:44can get a synapse and isolate that part and interrogate what kind of

14:50and ask what kind of molecules are there what amounts of molecules are there on what another

14:58i was going to be very specific but what what kind of of modification those proteins have we

15:05analyzed and we do different things like you can analyze behavior in an animal model do different

15:11patterns of electrical activity and analyze what’s happening with those molecules so in that region i

15:17have said that sigma is one of the most abundant proteins you have a collection of two more around two thousand different proteins

15:23so syncap is one more of these two cells it’s just one of these 2000 different proteins

15:29it’s one of the most abundant but you have tons of other molecules there so one question is that we’ve been trying to to address through

15:37the ears that what are the molecules that syn gap binds to and why that’s

15:42important for us because molecules that are associated together that just

15:48physically interacts so you have one molecule that they just bind to the other molecules that have that particular

15:54proper well the molecules that are associated one to another are usually um associated with the same

16:02disorders and this mutations in one of the other of these molecules are also associated with the same kind of

16:08phenotypes if you say that one molecule a mutation in one molecule changes the electrical activity of the

16:15synapse well a molecule that’s associated with the other with the other a mutation in that one also might change

16:21the electrical properties of of the synonyms and per se because of that they usually are

16:28connected with the same disorder so that’s something that i’ve been working for many years trying to address

16:33not just for singapore many of these molecules are the synapses like which ones are

16:39associated to which othersMass Spectrometry

16:44and we were doing this with the this kind of equipment which is called a mass

16:49spectrometer and we were doing a methodist mass spectrometry so basically what in this case what we

16:56are looking at proteins what the mass spectrometer will tell you is that you just put anything there any any any preparation there is going

17:04to tell you what proteins are there it’s basically working like that so for example if we know that we can isolate

17:10here the psd we do a preparation of the psd so when we say isolate synapses

17:16psd from neurons we we just put that preparation of the mass spec and it’s telling you what proteins are there so

17:21that’s why we know that you have around 20 more than 2 000 different proteins at the psd you can be more specific

17:28for example you can get a tool which is in most of the cases an antibody and this

17:34is for example zynga you get an antibody get sync up you just capture single from the synapse and just

17:41put that to the masses back and what it’s going to tell you is obviously you are going to find

17:46sync up there and you are going to find if there are other proteins associated to syngap you are going to identify what

17:52proteins are associated with zynga in the preparation so and that’s what we call a thing for example a syngap

17:58interactum which it means what are all the molecules that synap can bind at the synapse

18:05so and we’ve been doing these things for many years you have lots of variants

18:11that you can test you can test this and mutants in in animal models

18:16like having a mutation in singapore for any component of the of the of the psd you can do

18:22changes in electrical activity and measure how the associations of different components changes so thereProtein Interaction Network

18:28are uh different variants of working with that and we’ll be doing it through the years these are

18:36the kind of molecules that single binds to and you will see is a collection of this thing that triangles rectangles and

18:42things but what it means is that these are molecules that are fairly similar to sync up there are molecules that also

18:49bind to tons of other molecules so what it means there is a synthetic one of these components that are associated in this

18:56region of the synapse and and there are many molecules that share their characteristics and binds to many others

19:02it’s a it’s part of an intrigue intrinsically what we call protein protein interaction network so

19:08there are lots of proteins that are binding together and this is the kind of view what i wanted to convey to you there

19:15and we’ve seen the few slides is that singapore is not isolated we are not trying to address what is sync up doing

19:21alone at the cena but it’s within the context of all these molecules and this is for

19:26at least for us it’s a very very important point because the composition of these synapses is not the same always

19:33we are used to and most of our work has been in adult mouse models and we are used to i know a lot

19:40has published more than 20 years of work on sync up and what is it doing at this place but syngap is doing what is it

19:48doing within this molecular context because it’s associated to these molecules at this particular time and

19:56place from the cell so this is not much interesting to see for you it’s uh

20:02it’s just just to have an idea of the amount of different proteins that we are getting associated with syngap so what it means

20:08there is that synthetic has the possibility to regulate the activity of all these proteins

20:14you can see some of them as being targets some of them if you know that mutations in sync up and some of them

20:21are enzymes of proteins with particular function you can try to address what’s it do in a particular

20:26mutation and sync up to the function of other molecules so that approach is telling you you’re doing this just to

20:32see okay are some of this protein can be targets targeting means like pharmacological

20:38targets is something that we can do in the model of syngap like

20:43to try to recover functions not just of zinc but some of these other molecules so that’s

20:48just there there are many many of these molecules

20:53so it is what i was saying before they think these interactions this protein interaction from syngap

20:59change through development so the molecular context it’s different at different developmental time points

21:06singap doesn’t bind to the same things in an embryonic brain in a mouse to another adult synapse you have

21:12different partners what you can see here is that what we

21:19define in a protein interaction network so here is sync up each dot that you will see here around

21:26is a protein that binds to sync up you can do the same with other components on the synapse and

21:31trying to visualize what things are in common with other molecules why we would like to see what things are in

21:37common with other molecules because all of these molecules that are here like you see this name here the one shank three plg four are

21:46what we can consider disease molecules mutations in these molecules also can cause a

21:52number of historicals if you can see here in color code all these colors means like these

21:59mutations in these uh genes get you a disease why is this important because it’s

22:05understandable and i don’t know how focused always you will you need to be

22:10focused in mutations in sync up but there are lots and lots of things in common with mutations in these things in

22:16terms of these are in terms of signaling mechanisms

22:21in terms of phenotypes that you get in mouse models and in phenotypes that you can observe in patients they are part of

22:28a protein interaction network that regulates synaptic function at different

22:34developmental stations so the other thing what i was saying

22:39there is that this is a network of proteins a protein protein interaction network and why you we would like to see how to build up

22:46these networks and not just spoken in sync up even if the other molecules are involved in similar disorder because

22:53networks in general work any kind of network biological network social networks and in this case what we have here is an airport network works in

22:59a similar way you have molecules that are connected to other molecules

23:05and molecules that are not have many connections and molecules that have not many connections the molecules

23:10that have many connections we call them haves and for example if you okay here is lax and it’s a

23:16big uh circle there it means like have lots of connections if you get some of

23:21these airports in south america they don’t have many connections and what it means

23:26is when you disrupt in a network a component that has a lot of connections

23:32you have the probability to disrupt the whole network so if you having a slight delay in lax

23:40you can see that you are going to disrupt flights all across america europe and the whole

23:45world really if you have a mute if you have a delay in one of these airports itself or saying buenos aires here

23:51well nobody will care much you are not going to have delays all over the place and this is the thing with the molecule

23:57that i showed you before all these color codes all these things that you have there these are what we call

24:02hubs and synthetic is a hub in the synaptic network mutations in sick because it has a lot a

24:08lot of different connections you know the only one you have many have i told you that you have more than two thousand proteins so even if there were

24:15many things there in that picture it’s a very constrained and focused

24:21uh network it was i can understand that you will see there is a tons but there are no tones it’s a

24:26very defined network so syncap is one of these hubs and mutations in sync up had a high

24:33probability to just disrupt the whole protein protein interaction network as

24:38some of the others that i showed in that picture so that’s why it’s our interest

24:43to try to build up in this network because uh since years ago we we didn’t have

24:48this information to try to build up ourselves and now we have a pretty good idea what is the protein product interaction of the

24:54synapse and allow us to do different manipulations now again this is in adult mouse models

25:01and i keep repeating that because i’m going to if i have time because i keep talking these words describe about my

25:08human models so these are some names that i say forInteraction Network Molecules

25:14example these are all haps in those networks nmdr receptor which is a subtype of glutamate receptor and probably you hear

25:20about the foundation cure green this is another hub of the network this other molecule which is cnksr2 the

25:28hg34 they got one shank these are all molecules that are associated with sync up in the

25:34interaction network when you analyze mouse model all of these molecules are going to have

25:40deficits in learning memory synaptic plasticity different dysregulation of kinase and

25:46even arc two that probably you heard that you have this regulation of verb to activity in sync up

25:51you can do any animal model on this you are going to see changes in all of these things and you can keep reading and

25:56reading papers and finding common things but in humans also the mutation you have mutations in in humans

26:05associated with these disorders and you will find phenotypes that you will know that you will notice also

26:10from zinc and patients with many of these causes intellectual disability epilepsy psychiatric disorder

26:16sensory system dysregulation and aero development of the cervical molecules so all of this

26:22introduction of being singapore just tried for you to get it the message that syngaps is

26:28belongs to a large group of synaptic proteins and that’s a synaptic between brackets because

26:34we know that has functions that are not just synaptic

26:39and mutations in this set of proteins associated to a number of neural event disorders and they have some of them

26:45that have many common phenotypes and for you it’s it’s what is so you know how many

26:51parents association for many of these at least the ones that i know is just the cure green but i can see

26:56that even if that there will be a common ground in mechanisms and trying to join together and reach

27:02some other patients with mutations in these things sometimes you may see that a

27:07phenotype that you might have in what kid might be more similar to mutations in one of these

27:13than to another singapian for example you have this kind of variation they are part of a global network and mutations

27:21in the components are really associated so just to put together sync up within

27:26the context of all these molecules at the at the synapse so what aboutMouse Models

27:32everything that i say at the moment it was our knowledge in mouse models through the years

27:39so there were a couple of things in the last i would say five years that also it just turned my lab

27:46really uh more to still we’re working with animal models with mouse models but

27:53really focus they keep us a focus in in human-derived models and this is the

27:59capacity of generate um [Music]

28:04to reprogram cells and generate neurons from the patient sample that it can be a skin of blood we usually work with blood

28:10samples and the other is crispr method from genetic engineering that you can these

28:17days start just doing mutations correcting mutations on larger scale um these two uh

28:25methods just allow us out now at least to incorporate now bounce models so we are doing in general

28:32we have two different mouse models and i’m going to give some info on on one of them

28:38we can do and i’m sure some other picture from this but we can do a what we would call a homogeneous

28:46cell light model like you’re doing neurons in a dish or we can try to do an organoid type of model which is uh

28:54a model that tried to capture like more the cellular complexity of a developing

29:00brain so i’m not going to describe what we are doing with the organic model

29:06so for this i’m working with georgetown quadrature here at usc and now a new postdoc in hello which is

29:12marcella bertele which she just arrived from sweden and doing some quarantine now but hopefully

29:18she she can start working with us and for this project in organoid which we are trying to address syngap

29:25function in brain organized with different scale resolutions going with single cells

29:30multiple cell types uh the electrophysiology levels and

29:37different methods so we have a uh sr funding for for this week uh which is a project that

29:44is ongoing but i’m not going to to describe much of what we can do with that but we’re going to define what are

29:51we doing with this just to keep the train it’s with the neuronal phenotype that we already

29:57know so usually when this is the two ways that

30:02we would like to to to see how to use these models from the pharmacological point of view we will

30:08try to find uh trying to what we call improving or managing phenotypes like

30:15you could say the epilepsy eating disorders sleep behavior or you can go and that

30:20would be just what particular targets and compounds and the other thing you can go and

30:26use your model with stem cells and genetic sheen editing mostly for you don’t need to know much

30:32about what is it doing or cellular composition but you would say okay we were trying to recover and improve sync up

30:38protein levels other protein functions for those uh approach for both

30:44approaches you have uh at least four different things that we are

30:50focusing one is to get a target in this case it would be a particular molecule as itself as what say uh within uh

30:58the synapse for example or in this case obviously your target is sync up

31:03you will have a compound for that target or machine editing you will need a delivery mechanism and you will need a

31:09proper model so the thing that i’m going to describe is what it means this proper model how are we using the model obviously all

31:16these things are important and them is just referring to to what is our model so why we are using

31:24human models so human models at least have two uh to me two main characteristics that

31:31that’s why i like them is you’re working with a property with the human shin with all the regulatory elements and this

31:37is absolutely essential for all the sheen editing

31:42approach and also you are working with the genetic background of that particular patient so is

31:48by allowing you to answer questions like okay the phenotypes that we are getting or all um with this particular patients

31:57what is the component of the single mutation and what is the component of the genetic background of that

32:03patient that could be higher lower or maybe not important at

32:09all but it is something that i think that we will need to answer uh in the next few years or at least as

32:15soon as possible what is the component of the genetic background for the phenotypes that we

32:22are observing in the patient within different patients and as i said with the human models you

32:27have a homogeneous model which is a single cell type we can work where you can do these days a glutamatergic neuron

32:33you can do a gabaergic neuron which is inhibitory neurons serotonin inertia in the urine and this is something that we

32:39like to do because we have a homogeneous cell population that we can answer a particular question what is doing sync

32:46up in that cell or the tetragenesis model which is in brain organisms important to know this is the first

32:52thing that i would the first time saying this i’m going to repeat it many times

32:57from here to the end of the talk all these human models are immature

33:03models are fetal like models and they are poorly characterized what it means with this is

33:09the synapses that you are getting from this uh from these neurons it could be in a

33:14brain organ or or or in single cell types are fetal like

33:22these are not the same uh synapses that we were being used to work through all these years of

33:29single biology what they are resemble is not this mature synapse of the mouse it’s just

33:34a fetal like uh synapse in a human and i would show some data on thatCell Therapy

33:44so for both these models you have might have two approaches and you you can

33:52this is the thing that this is more than you know of cell therapy approach so for example you have a syn

33:58gap one patient would usually work with a blood sample you reprogram those cells you then

34:05induce purpose stem cells from that sample and then you would like to differentiate

34:10it to neurons a particular cell type and what you are doing in general in this case is just trying

34:16to model have a model in a disease in a dish in a single cell like

34:21a single single cellular homogeneous cell types or

34:28there are also approaches these days that you are trying to repair those cells

34:34and get it back to the patient but this is not something that we are much interested for synchronizing absolute molecule that is

34:39just in the the whole brain every most of the cells express synapse but there are approaches that i will go to

34:45at the end of the talk that might be of interest for this uh for this case not just to get back

34:53healthy neurons but it might be something to consider or at least that we would like to explore it’s but

35:02cellular neuronal progenitors are the particular cells that might be of use and this is

35:08something that we are starting to to to address but that will be discussed at the end soMutations

35:17thanks for with many of the patients i don’t know how many uh parents are might be discussing how many

35:24parents get me that might be hearing now gave me samples to for

35:31studying singap function but we have a good number of uh mutations of zinca

35:38these are just these balls there is where are the mutations located in many of our samples i’m going to describe some data with a

35:44mutation that this is a truncation mutation here at the rascal domain and a different mutation

35:50or nano splice inside more close to the c terminal

35:55so this is some data one let me see yeah so when you get your

36:03sample what you always you get with well and you generate the neurons one thing that you always do is what you

36:08correct the mutation so what it means is that you just put back the the normal base but whatever is the

36:15mutation you just correct it back to normal and that’s your control so you are controlling there for the particular genetic background of the patient

36:22and and you need to do that for every single sample that you do in this case here is what is called a

36:29western blot what you see these things there are sync up all on this

36:37line and what it means see is the corrected patient that you see what you see in a western

36:44blot is i mean what you measure here is an intensity it’s not a good way for to measure an

36:50essential and we do everything for mass spectrometry this is just for illustration there i

36:55hate this kind of representations but it’s useful for talks and also reviewers

37:02likes them and they used to complain of silly singles which is the size of this everywhere because it looks like if you

37:08see it it’s real and nothing nothing something like a mass spectrometer

37:14but well this is how in science works it’s a mini range on that but what

37:20this means here is a corrected patient this is a knock out this is a patient that doesn’t have sync up at all so it’s a

37:27control for us and this is the patient this is corrected no control you can see that

37:33uh and this is wrong because this is the patient and this is the

37:39corrected so this is the pension you don’t see much sync up and in the corrected you have more again

37:46this is the patient this is a corrected in another clone and it has more this is the patient

37:52nothing correct you have more so you will say that in this case that mutation decreases the

37:59amount of sync up from that patient to what extent what you would say you can do a quantitation on this and you can say

38:05that is around a 50 percent which you would call a happily sufficient model

38:11and i would say something of this about the end of the talk this is not a good

38:16way to do it and i was just showing by by western blotted but we will need to get better

38:22and this is where working with this to generate a reliable model

38:28to really properly quantitate for each mutation in patients how much synapse is in there and

38:36there might be the cases that you will say yes is a 50 roughly 50 or something but there might

38:43be that some patient have a 50 another patient has a 65 and that makes a huge

38:48difference in the phenotype i’m not saying that that’s the case i’m saying that we don’t know and this is a very big

38:55concern that i have at the moment so we can derive neurons you haveImmature neurons

39:03different pictures of neurons that we do these are human neurons from from patients with mutation in sync up

39:11so you’re not going to have the eye of what it means to be an immature [Music]

39:17neuron within mature spines but you need to believe me that when you see a spice like this like

39:23you see like not much a shape like a hair if you want or something that’s protruding

39:29from this green line which is what we call a dendrite these are immature spines

39:36you would like to see spice more like this you see like kind of mushroom thing and you would

39:43like to see tons of them when we were working with mice you will have

39:49tons just complete the dendrite completely full of three things

39:55are these neurons are behaving like an immature cell even if this is the three and the difference

40:01between these and this is because this having been uh keeping culture by three weeks and in this case we were

40:07being keep in culture for eight weeks and you will say okay you can keep them in culture for six months uh

40:14you get it better well you’re not going to get much but we never got it for six months but you’re not going to get it much

40:19better and because these are human cells and they follow the developmental

40:25profile of the human cell so even if you culture for months and months you are not going to get to that

40:30and also it’s really practical for any purposes just getting an experiment to run for years

40:40oh um again if you see what it will be sync up around there is sync up

40:46would be you know if you’re going to see it but synchro is going to be at the tip of that spine that red thing there is not sync up is

40:53pse95 which binds to sync up so think of it’s generally in in that region so one thing with this is

41:00that what we are working with synapses and if you see this

41:05you will straight away think that it’s very very difficult to work with sync up in these

41:11models because you don’t have many spines you don’t have a lot of sync up in these cells as in a mature synapse so that’s what we

41:18need to get better and better in trying to characterize the cells and trying to develop models that allows you

41:24to work with sync up in these cells so bottom line with this is it’s not the same

41:29cell type it’s not the same the cellular context is different and it’s really difficult

41:35to work with sync up in this condition these are for example with one of the samples in the patient a corrected cell line that you see

41:41firing of those neurons that we can record in multi-electron rays and this

41:47is a producer control or a corrected cell line and this is the mutation

41:53just if you look at this you will hopefully you see that the one at the bottom with the mutation you see

41:59more firing so at least these things are burst will is a it’s a measure of the

42:06of the network of network activity of your culture so you will see that this

42:12morning you will see here is you have suddenly traced recording here uh you will see that you have more burst

42:18in the patient which is more like you would say is firing more in this caseCharacterization of immature neurons

42:26so i knows how much how i’m doing with time it’s not good is it no i think

42:32the the i’m hearing the people are enjoying this a lot so please keep going um because these are just pictures on

42:40showing proteins that are present at those neurons that i said that are immature so

42:45the first thing to me was in characterizing these cells it was okay what things can we do

42:50in a cell that is is in a neuron that is a fetal like neuron and to me what’s the first question is okay

42:56we have sync up there how much sync up in relationship to other molecules because we knew that it was one of the

43:03most abundant proteins in the mature rodent synapse do we have all the other components these components that we say

43:09that are associated with disease and all these protein protein interactions that i show you are there

43:15and first question to me was if those even if those cells had psds or no which is what this thing that i showed you

43:21before in an adult mouse that is electro dense region well so i spent hours on an electron

43:27microscope myself trying to see on this and yes i got pictures and here and here you see these

43:34electrodes here and in the red part there but what i would say is that and this

43:41there’s not plenty i spend hours and hours just chasing psds so which is obviously

43:47obvious because you don’t have so many spies in this so it’s difficult to get but next thing is can we characterize

43:54those psds even if you don’t have many synapses so these are western blots and

44:02these are all names of molecules that we thought that are we were interesting to see if they

44:07were they are or not so this is if you say when you say soul it means like that’s not the synapse is

44:14for example soluble what it means is like this molecule should be around here or there but not here

44:20whatever is psd it means things that we are isolating from here and this is like something like you

44:26would say a control so if you say this is a subunit of nmda

44:31receptor we look at the psd yes we can see it in the other region not much the same

44:38with another subunit of ndi receptor this is a different type of glutamate

44:43receptor it’s in both as expected i was expected to have it in both

44:48this is a protein that this should be localized here at the presynaptic site and you see that we we don’t have much or anything

44:56at the at this end and it’s there so which is good ampa receptor which probably you hear a

45:02lot down if you hear a lot but you should have here loadable upper receptors in in some of the talks but again we can

45:08find that there are other molecules and we were pretty happy this doesn’t mean

45:14much this means that the molecules are there and next thing i was looking on a human

45:21fetal brain and we found similar patterns so what is telling you is not much so what you will

45:26say is that in a human fetal frame you have this molecule that have we have been study

45:32as well in in a mature synapse the amounts are not the same

45:38it’s difficult to work with but to me at least this is telling you that you can still answer questions

45:44related to synapse function at the psd in this cellular model you need to be careful and i’m not going

45:50to go into many details on this because the composition is not exactly the same of

45:56the market but it’s still it’s something that can be used soCharacterization of genotype

46:02you will see many in in different kits that you you you’ve seen you are obviously you

46:07don’t see the same phenotypes i mean different mutations get you also you know in a dish

46:13different phenotypes for example this is electrical activity and you say here is the patient with the

46:20mutation one you see this pattern of electrical activity which it means that is higher comparing

46:28with the control you have in this mutation here you see the pattern of electrical activity is

46:33completely the opposite it’s lower and that’s what i was saying you would need

46:39if you want to get the proper characterization characterization of genotype which is the mutation and phenotype

46:45which is your observation you will need to know very well what the mutation is doing

46:52to the protein how much protein if you have a truncation if here is produces some

46:57partial uh uh is it’s just a partial protein that you get

47:02if it is a complete wipeout and you um you have happily sufficient model this is something that we need to get

47:08better to know you can analyze how numbers of spineSpine morphology

47:14morphology of the spine you see for example in the first case the the

47:19the phenotype that was having a larger electrical activity you see that well

47:26you don’t you’re not going to see much here but you need to believe me that you have more spines in this case with this mutation that in

47:32the corrector that you look at here you have what we call a spike intensity so it means like in the patient you have

47:39more spines and also they are bigger you have in the second case you don’t

47:47have any difference in spine density and also volume which is not shown there so you have different

47:52mutations as you expect or not but you have different mutations

47:57they are producing different phenotypes and the clinical phenotypes of the benches also it’s

48:03different next thing that we would dig with this with because for us was important it’s okay it’s all thisBiochemistry

48:10thing it’s as i was saying that you have don’t have many spines and the amount of material in each one of them

48:16is not as much as you would expect from a mature synapse is like can we do biochemistry which is biochemistry means

48:23that work with the proteins in the same way that we were working in a mouse model so we were trying to do the same things

48:30like we always did with the mouse model isolate synapses isolate the psd and start

48:37interrogating what is in there by mass spectrometry

48:42so we were doing that and i’m going to show some pictures and don’t pay much attention because there are lots of numbers and things so the

48:49only thing is for that is that we can monitor what’s going on in the synapses from uh

48:57derived from patients and with different patients and we can see differences between one and the other

49:03uh what it was i was saying at the beginning a larger scale without what i would like so for example we can

49:11prepare these psds from these neurons we can correct

49:16for each one of them you have different clones this is i’m not going to technical but things are not very reproducible while you work

49:21with this so you will need to have tons of control so these experiments were working really really nice because they were really really

49:27reproducible between different clones and you can start quantitating changes in the total number of proteins changes

49:34in particular uh what we call this is going to be post-translational

49:40modifications which is mean protein phosphorylation for example these are things that that

49:45you produce a change which it means increase or decreasing phosphorylation in a protein and that produces a change what it means

49:52is the cell needs to come to communicate what is going on from outside to the inside i

49:57will say how does it do it you have a molecule that senses something and then transduces what it sends into the inside

50:03of the cell lots of these things happens by what we call protein phosphorylation so it’s

50:09getting you an idea what’s going on how you respond to that so by monitoring changes in

50:14protein phosphorylation what you try to address is that what’s going wrong in all the signaling mechanism so okay

50:21you have a mutation in single but you want to know what what is wrong within the all the

50:26cellular mechanisms the signaling mechanism of the cells so when you do it a larger scale you have a pretty good picture on that and

50:33we got like more than a thousand phosphorylation sites and in in these samples and we can

50:39monitor changes in phosphorylation in one we associated with one mutation or another for example in this mutation

50:47we got more than 100 phosphorylation site that being changed and in this one we were more than 300

50:53you have some going up some is going down and then you start to building up what uh what is in common or not how it

51:00might affect the protein interaction network so we start saying okay which molecules are affected which molecules are not

51:06affected we’re trying to build that the same thing that we will already know from the uh mouse model

51:13with the patients really that’s the bottom line the difference is like okay we have now real mutations that

51:19happen to real people and within the context of a human cell with a particular genetic backgroundCellular Model

51:25so what i would say with this is that even if you have all these color codes and think that i think we’re pretty happy that we have

51:30a robot’s cellular model to monitor sync up function in this cells it’s working really well

51:37and it’s a lot of work really because you can say what things that are not abundant means like you need to

51:43culture tons tons of dishes and and it’s limited anyway even if you

51:48culture tons of dishes if you don’t have many synapses you increase more background than the number of synapses

51:54but it works well so we’re pretty happy you can you it’s not the same thing as i say and i

52:00will keep repeating it’s a developmental synapse but we have a model uh

52:06model that we’re pretty happy with that we can monitor changes in syngap functionExcitatory Neuron

52:14the other thing is like where everything that i was saying is an excitatory neuron what it means an

52:20excitatory neurons that you see here is i don’t know why is this blood there but well syngap used to be in synapses

52:26around the dendrites around here and everything that i described is what

52:32we know in excitatory neuron what is the mean excitatory neuron it’s like what it really is here from that terminal is an

52:38excitatory amino acid which in general in this case is glutamate that’s why this is an

52:44excitatory neuron you don’t have just sync up is not just expressing excitatory you have lots of different excitatory

52:50neurons different types of neuron depending on what is releasing those physicals if

52:55it is glutamate in this case is the neuron that i described an excitatory neuron

53:00if it is gaba it’s an inhibitory neuron what is going to do that neurotransmitter on the

53:06neuron that it makes the synapse is just inhibit that activity it’s a completely

53:11different thing so even on all these if you have dopamine dopaminergic neuron it releases

53:17dopamine serotonin aerosic neuron releases serotonin so most of what we know it’s the

53:24description is this type of neuron sync up is expressed in many other neurons

53:30and we don’t know what is it doing we don’t know what is it binding and really we don’t know if

53:38if it is really what what where can that help us to understand or

53:44find new therapies for for mutations in singapore but i wish you some

53:49um a little date on that so good thing with these

53:56human models now is that they are pretty no machines when i say pretty homogeneous is that okay we have protocols to from the blood

54:02sample to do an excitatory neuron and most of those neurons in the dish are excitatory neuron and this seems

54:09obvious or maybe it’s not also important but when you are used to work with a mouse brain

54:15getting this level of on machinity and just to address a particular question is very difficult because you cannot get

54:21just an excitatory neuron from the mouse brain you get a mix of things so getting just one

54:27particular cell type on your dish for us it’s really important in that at least for

54:32answer a specific question so we did the same and we just that’s i showed you for excitatory units

54:37with gabaergic neurons so this is inhibitory neurons you can see this big blob

54:43there is that sync up in excitatory neurons uh to our surprise it was quite abundant

54:49this is a very relative thing what is abundant or not it’s in it it’s i could say that is comparable to

54:55what we found in the excitatory neuron so obviously we can immuno isolate here

55:02sync up which is what is shown there we can get it to the mass spec see what is it binding there and start to address

55:07questions of what is it doing at the inhibitor neuron and when you start playing with different neural types you can start

55:13doing different things for example if this is an excitatory neuron that would i show you the electrical activity

55:19here which is a multi-electro array these are electrodes all these things there and you see these

55:24kind of white things are neurons so you record the electrical activity there that’s what we showed before with the

55:31excitatory neuron you can do the same with the inhibitor neuron now and then you start playing with things like for example culture in an

55:37excitatory neural and an inhibitory neuron and measure electrical activity you can measure activity of both

55:44mutations in excitatory inhibitory you can have in your dish

55:49a mutation in sync up only in the excitatory but you can have and a dish with

55:56mutations in sync up only in the inhibitory neurons we are doing the same thing also with

56:02dopaminergic and certain inertia itself important thing with this is as i say

56:08that if we can address some of this function and something that it might be interesting in terms of

56:15a question that would say is it important to at least restore sync up function in inhibitory neurons

56:22because there are protocols and they are being just uh is at this moment there have been

56:28clinical trials on patients being um treated with

56:35in neuronal precursor it would be neuronal progenitor cell from inhibitory

56:41neurons what you get in your brain is pro is a cell that is going to became an

56:46inhibitory neurons and that’s been treated mostly the idea is we will have some work on

56:51epilepsy but you can think about is that if we if really sync up has a function and is important in

56:57individual neurons that might be something that might be worse to explore what it might be

57:03and the consequences of what might be improvement within restoring sync up activity at least just for individual

57:09units that’s why we are interested in in thisGenetic Background Effect

57:15because i think to finish genetic background effect i think we’re i’m something that we

57:22like to and we are already doing this is just to try to address what my is the

57:28effect of the background of the mutation what we are doing with this for example you have here a mutation which is this

57:34in purple circle there and usually what you do is you correct

57:40it and you hear you turn into green you have a different patient with a mutation here in blue and you correct it what we are doing now

57:47we’re trying to address is that what is it doing the mutation from for example

57:52the patient one within the genetic operation two with the genetic background of patient

57:57two so what you have here is that you correct one patient and then you introduce the

58:03mutation of a different patient in the correct background of the first this looks

58:09uh it’s difficult but what you are doing is as you just correct it you get a normal

58:14uh cell line and then you get the mutation of the other ether and

58:20then in that case you say okay we’re really interested in this and trying to address it that for example

58:25happily sufficient model would get you the same phenotype in one background or the other and different types of mutation this is

58:31something that we don’t know and then is obviously you will try to get the different characterization that

58:37we are doing so finish to finish

58:44so we think that this is really important and something that we are pushing forward and getting trained to the determined

58:50effect of mutation in singapore it’s what is really doing

58:55when you get from your genetic consular essays

59:01mutation in syn gap and it’s predicted truncation or something that’s predicted and we don’t have a

59:08real a good method now to tell what is really going on what is really happening to the

59:14protein to the protein levels or at least to the structure of the protein we are analyzing different cell

59:23types and we will need to have this better characterization of cellular model though we are kind of of different cell types and what we

59:28are getting yes well you expect to get this method pretty soon we are trying to do it by mass spec

59:34we have at least a cellular model to address this and we are

59:40also getting this different cell type to try to address alternative targets and pharmacological approaches for

59:46cell-based therapies and this characterization of

59:51of the models that i say i don’t know that was really clear but one thing that is really important if you are going to

59:56move forward in shin editing approaches these human models are the proper way to address it

1:00:02you are having the background of the patient you are leading with it with the machine with the human chain of sync up with all

1:00:09regulatory elements so it’s what we’re likely to to try with these models now this is the people that

1:00:16we working in the lab people doing massive spectrometry collaborators in different uc’s

1:00:22and shore shadow and i’ll say marcella that we are carrying forward with the help of the

1:00:28srf the organoid model that hopefully probably she marcella or now anyone can

1:00:36talk pretty soon next year when we we don’t have so many restrictions with copied and the things that we can

1:00:42start going back and work at full for at the lab so thank you and i know you have a question

1:00:50i think that we are getting questions afterwards yeah yeah yeah thank you so much marcelo i’ve um

1:00:56you can i think you can take down your slides i’ve enjoyed exchanging messages with a few families during your talk

1:01:02and all the scientists have and people with medical training have enjoyed

1:01:07all the science and the non-scientists are asking you know also enjoying knowing

1:01:13that there’s so much good work going on um i want to just

1:01:18so i want to just start by saying how grateful srf is that we are in touch with you and that we’re

1:01:24working with you and and i’m glad we have this webinar just so i can show families the breadth of

1:01:30your work and the depth of your knowledge so they can understand why we’re where we’re working to get you a postdoc

1:01:36in your lab but again but and as you know because we’ve had some conversations before the families

1:01:43ultimately are thrilled with the science but want to understand

1:01:48really simply how this is going to how research will affect treatments for their kids and as

1:01:55a pharmacologist you know you think a lot about treatments so i can you just

1:02:01in in the simplest simplest terms explain to parents why your work

1:02:08in in human models right so you made a very good point earlier a lot of people when you work in mouse models of one

1:02:13kind of neuron but now you’re doing human models and you’re putting you know one kid’s

1:02:18mutation in another kid’s background so as to see what we can learn what can

1:02:24you just in simple language answer why is this

1:02:29why is this going to help us as we start thinking about therapies yeah i would think one other thing you

1:02:36need a model to at least you need to characterize well your model to know what you are

1:02:41first what you are looking for you’re saying that you are trying to correct sync up right what does it mean what are you

1:02:46going to look for yes we are focusing getting model it’s in because you know the fee what you get

1:02:54is that there are people from lots of different places trying to do this with lots of different disorders it’s just to correct

1:03:01a mutation really with lots of different things an important thing and i and i have this

1:03:07talk with people on uh with pharma companies and people working they don’t have a clue on what to look for

1:03:13right and what are you going to to get you are going to you’re trying to model your

1:03:18classic mature neuron and trying to see what is zynga doing there when you don’t have many of these

1:03:24molecules are you expected to just to almost have very very little amounts of sync up

1:03:31how are you going to monitor changes in are you you added thing up and you

1:03:37say okay you have a hapless sufficient you have your chin is decreasing to what level to what level you need to increase it

1:03:43to start seeing something these are if you want in a way if secondary things if you wave

1:03:50you will say okay first i want a reliable method to edit it we are working on these things as well but this is not what i presented

1:03:57what i’m saying is that something more general that needs to be built up is that the proper model system to test

1:04:03that whatever you are doing it works uh i don’t see that we have this at the moment and

1:04:11because the model it’s you i would say you need to do it in a human model

1:04:17but you need to understand the model that you have and maybe you don’t need excitatory maybe you can start working we are

1:04:22thinking maybe we are doing in the inimitary neurons we see that at that in this particular cell we have more zynga but it’s more

1:04:29easy to work with so these are things that yeah that we’re working with and it it’s working fine

1:04:34but it’s not easy so it needs all this characterization that we were doing and that’s i think that is something

1:04:40important that needs to be done great um okay i’m gonna start reading you some questions that have come

1:04:46through the q a and i would encourage the families and the scientists to um put their questions there please

1:04:51um and and with apology to the scientists i’m going to take parent questions first but i will try to get through all of

1:04:57them so one question from jr when you have a fast assay for protein levels for each

1:05:04mutation will that require blood donations or will you recreate the genetic variant in your own cell line

1:05:10yeah when i say fast uh it’s not like we have a blood test

1:05:17and we say what is happening is fast for our standards is you what i would say is that well you

1:05:23will need to go through these processes you will need to get your blood sample get your cell line

1:05:29a culture that’s a line and then when you have an amount of syngap

1:05:34uh yes measure the what in that case in that case will be

1:05:40fast after you get your neurons and then you go that will be by masses back

1:05:45and knowing what to look for and address these are things that i they need to be

1:05:51like that is you there’s no way around unless you want to work with mrna which i want

1:05:58um okay thank you next question jr is interested in the two singaporean

1:06:04sufficiency models of different ages for the neurons i think this is her

1:06:10talking i think you have a variety of observations in both and that they are different is that right i cannot for one of the the ones that i

1:06:17show for one of them i can see and that that’s what i i cannot

1:06:22tell that one of them all is happy sufficient i cannot i cannot tell i still don’t know that’s

1:06:28what i mean i need a we need a method it’s simple if you do that thing that you see in the western blot

1:06:34you do some samples and you do some stains there and you say there’s more or less but that cannot tell you if one model is

1:06:4050 of the other 65 percent i cannot tell that i know that the patients are different they have

1:06:45clinically they are different and in my mind i cannot think that such differences are

1:06:53coming from both being highly sufficient models because otherwise i don’t know where we’re starting really if every happily

1:06:59sufficient it’s completely different it has are you going to i don’t know it might

1:07:05be genetic background there are different things but that you will need to check i would

1:07:11really want to know yes how what is it really doing in each case the protein and then you move forward

1:07:17that’s what i mean the methods at the moment are not telling you they’re not so precise right

1:07:24one of the things and then i’ll go to powell’s question um which is at the bottom of the q a if you’re reading them um one of the things i say to people is

1:07:32generally when we’re talking about syngap researchers a lot of the work is focused on a

1:07:39certain kind of neuron at a certain kind of age and as the research that’s coming out just in the past couple years about the different

1:07:45isoforms of syngap that you have been you’ve been an author on some of those um

1:07:51you what you’re really digging into and please tell me if this is right what you’re digging into is is the is

1:07:56the different functions of syngap in in the different types of neurons and at the different stages of development

1:08:03and that’s work that really has there hasn’t been enough done there yet is that am i being

1:08:09accurate when i say that yeah you don’t think that you know it’s

1:08:14lots of time in science it’s not like we’re trying to get to the menu my new details

1:08:21or knowing what exactly to do everything because what you need is a solution and

1:08:26i totally understand that and i’m looking for that but there are

1:08:31things that it might look my near to you that it’s at least there are things that i

1:08:37need to know first to to then move forward we don’t need to know what exactly each isoform

1:08:43is doing in each cell type to get uh something working on but there are things that at least just to

1:08:50characterize the model knowing what to look for there it’s important that maybe uh in that

1:08:56case is that should we look for a particular isoform in this model i i don’t care i mean it might not care

1:09:02what is match what is if it is for correction for pharmacological approaches yeah you

1:09:07would need to say okay or build these networks and say where it might be other targets for corrections

1:09:13is different i don’t care which isoform but at least i need to know which ones to look for

1:09:19okay thank you and then uh i don’t know if you’re reading them but powell’s question um if i understand correctly you’re

1:09:25trying to determine some of the compensating effects of other mutations in the genetic background on the phenotype

1:09:31could this unearth other targets for treatment especially in the case of quote-unquote mild patients do you have any idea

1:09:36the relative balance between this type of synthetic mutation and the possible effects of other changes in genetic background in the resulting phenotype

1:09:43yeah shouldn’t it yeah we’re working on that we would see and but that that’s when you we’re

1:09:49working with that you’re getting really specialized medicine issue you’re just dealing with one patient

1:09:56yeah and uh when you say genetic background is super

1:10:02it’s really really why it might be something like are just variants which means your mutations

1:10:10that per se are not getting you a different phenotype but they are influencing which

1:10:16is really really tricky to know what is going on but sometimes and we we are

1:10:22looking into this there are patients with mutations in components that you are saying okay this

1:10:27might be doing something else and because yeah it’s not just one sync up mutation at the end is you have

1:10:33yes you might have mutations in other sheets that are doing something more dramatic if you want you can

1:10:39actually go that background but those are more easy to tackle if there are variants

1:10:45through a genome it’s yes we are doing meth we are doing assets just to to see if

1:10:50that has a an effect um but yeah it takes a lot of

1:10:56time because you know you need to correct one patient and get the mutation on the other and that is just true we are not

1:11:02planning to do this for every everyone but at least that would tell us role of background

1:11:08define things we are planning to do that in happily sufficient models and say okay it start behaving the same with the

1:11:14different backgrounds knowing what are the clinical characteristics of the patients got it um

1:11:22i think that question has been answered and then sydney is asking the last question you shared about how the molecules that syngap associates with

1:11:29change depending on the stage of development would we expect that mice that have their syngap levels reduced would then have

1:11:35an associations with other molecules that is appropriate for the chronological age and non-mutant mice

1:11:44and so let me read it yeah it’s at the bottom of the list it’s um

1:11:53would you expect that mice would you expect the mice that have their syn gap levels rescued would then have

1:11:59associations with other molecules other things other than the normal ones

1:12:04yeah or other proteins maybe well the lots of these things in the cell it works by

1:12:11molecules being on the right place and in a particular amount when

1:12:17you say that the molecule binds to another it’s because the structure of these two molecules that you have a shape and the

1:12:24other binds like this but that’s what we call affinity when you put a lot of something affinity

1:12:29doesn’t matter much you just go and it doesn’t matter so if i don’t know that

1:12:34having a correct interpretation if you say if when you rescue you see some

1:12:39uh it could be that if you are putting tons of zinc out binds to lots of other things and

1:12:48but i don’t know i’m answering that and then mouse model

1:12:53it’s okay i will expect that if you ring i don’t know it depends on what

1:12:58is the metal that you are using for that rescue but i will sync up is really about with

1:13:04all what i’m saying is that yes you would have a developmental phenotype i don’t know when you get a late rescue you will

1:13:11in a human you will get uh what sort of or phenotypes are you going to recover

1:13:18that’s not no and i wouldn’t care much about that because

1:13:23you cannot do anything whatever you if you have a rescue you should do it

1:13:28and if it works it work whatever it is getting what to work works yeah um

1:13:35two more science questions uh shan wang asked have you checked the ei balance in your human model

1:13:44i don’t know what e.i balance means which one it is third from the bottom

1:13:56no we still didn’t do the i suppose the excitatory inventory i guess uh no we still at the end of it okay

1:14:03cool and then since you’re reading them let’s just go down from there jamie jenny weed asked i’m especially interested in the

1:14:09background differences and how they might affect embryonic brain structure are you seeing that now

1:14:14we still don’t know we are going to to do that yeah great we already did that those

1:14:20swaps yeah we still don’t have the results yeah so we see that different syngat patients have different reactions to

1:14:26different anti-epilepsy drugs is this something that can be investigated using human cell models

1:14:31yeah yeah okay cool now well we don’t know it

1:14:39that’s something that you can do i know the correlation yeah but i would say [Music]

1:14:45those models are suitable for that uh other option is going with rodents well

1:14:51you’re not doing it’s you cannot get background the proper change yeah yeah um okay then there’s this um

1:15:00and then there’s this these three questions from anonymous one of them is asking about what i sing up isoforms are another one is

1:15:06asking about can organize feel and thought about that one before and the last one is how can mutations

1:15:12of which all are expected to reduce ingot protein result in opposite phenotype and cultured human neurons

1:15:18i don’t i’ll let you um well that’s what i was saying that we would need to reduce

1:15:24sync up protein that that’s knowing what is really doing the the mutation

1:15:31if you say that that’s perfectly understandable thing to say that okay you have hypersufficient that decreased

1:15:3750 percent of sync up in this patient and in this one how are they different and you will say

1:15:44in cultural human neurons you might say oh that’s an artifact but the patient has different that’s why i

1:15:50have different clinical phenotypes so it’s not just that you are seeing that there but what i that’s what i was saying is

1:15:57that we need to be sure or what the mutation is doing

1:16:02to start to answering that question and if that’s the case you can start

1:16:08being the next question is just start looking at the background

1:16:14okay got it well with no further questions i want to just thank you so much dr koba

1:16:20for for taking the time to let us see how your brain works

1:16:25um we’re we’re excited to keep working with you and we look forward to seeing what you come up with

1:16:31martha do you want to i just wanna say thank you this was

1:16:36great i think i hope all the families can understand the work we are trying to do with you

1:16:42because it’s it’s very exciting i think it is gonna help us a lot we we really hope everybody yeah got a

1:16:50good course of what you are doing because it’s great and thank you marcelo thank you thank you thank you yeah

1:16:57yeah and i just want to end with um that said we we due to

1:17:03just the scheduling and changes and schedules we do have another webinar tomorrow so if if

1:17:09this didn’t make your brain hurt enough you can come back tomorrow

1:17:14and i just want to share this um singapon sanders this is dr dr sanders from ucsf we’ll be

1:17:21talking about the developing human cortex and since i’ve got slides up i’ll just go through them

1:17:27um we also have the syngap uh roundtable scientific roundtable with

1:17:34a lot of remarkable scientists including dr koba so we told dr koba this was for parents and he should keep it simple

1:17:40so i cannot wait to see what he can talk science at the round table so i cannot wait to see what he presents at the

1:17:45round table but um mary kennedy he was one of the earlier scientists in singapore and is still

1:17:50busy at it caltech dr heller from penn roomba from scripps dr koba’s on the screen ellie talking

1:17:57about our natural history study dr smith hicks from hopkins al george who i think is on glad to see him

1:18:02and of course our very own han schleck talking about srf so syngap.fun rt2

1:18:09please come um we do have a natural history study you can join right here if you’re a parent who’s not on it

1:18:15saying fun slash citizen two eyes um we’re selling stuff everybody loves

1:18:21these sweaters sing fun slash be kind if you can still order in time for christmas

1:18:27and then just a reminder this is tomorrow don’t miss it and if you have questions or comments or feedback and you want to talk to me

1:18:33syncgab.fun mike thank you all very much and uh special thanks to dr koba and we

1:18:40look forward to working with you for years to come thank you i think we’re done thank you

1:18:47bye everyone

« All Events